ArticleEClinicalMedicine2022

Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study.

Guoliang Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.